San Diego-based Genalyte Inc. won a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of type 1 diabetes.
The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.
Genalyte's novel multiplexing technology simultaneously screens for the detection of multiple autoantibodies and other proteins using a one-step, 15-minute process.
Genalyte's Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.
"The unique capabilities of our Maverick multiplexed detection platform have the potential to provide researchers and clinicians with the tools to detect and track this process from a very early stage, when therapeutic intervention to interrupt the process could be feasible," said Martin Gleeson, Ph.D., chief scientific officer of Genalyte.
The SBIR-funded program initially will create a basic multiplexed assay to detect autoimmune response for known targets for type 1 diabetes.
It will then expand the approach to profile autoantibody response by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.
Once the autoantibody panels have been developed and tested, they will be refined and validated using samples from patients with type 1 diabetes.